ReviewPharmacogenomics2014
Genomic architecture of pharmacological efficacy and adverse events.
Review in Pharmacogenomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).Clinical pharmacology and therapeutics · 2019Trial
- A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes.Clinical pharmacology and therapeutics · 2020Article
- Open Humans: A platform for participant-centered research and personal data exploration.GigaScience · 2019Review
- Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene-Gene Interactions.Frontiers in pharmacology · 2018Article
- Lessons Learned From Past Gene-Environment Interaction Successes.American journal of epidemiology · 2017Review
- Personalized medicine: Genetic risk prediction of drug response.Pharmacology & therapeutics · 2017Review
- Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.Nature communications · 2016Article
- Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits.The pharmacogenomics journal · 2016Article
- Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network.Clinical pharmacology and therapeutics · 2016Article
- The genetics of drug efficacy: opportunities and challenges.Nature reviews. Genetics · 2016Review
- Uncovering drug-responsive regulatory elements.Pharmacogenomics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. Pharmacogenomics-based tests are already being applied in clinical decision making. However, despite substantial progress in identifying the genetic etiology of pharmacological response, current biomarker panels still largely rely on single gene tests with a large portion of the genetic effects remaining to be discovered. Future research must account for the combined effects of multiple genetic variants, incorporate pathway-based approaches, explore gene-gene interactions and nonprotein coding functional genetic variants, extend studies across ancestral populations, and prioritize laboratory characterization of molecular mechanisms. Because genetic factors can play a key role in drug response, accurate biomarker tests capturing the main genetic factors determining treatment outcomes have substantial potential for improving individual clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.